Lv5
1020 积分 2021-11-06 加入
Understanding and overcoming multidrug resistance in cancer
2天前
已完结
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study
1个月前
已完结
Rational combination of cancer therapies with PD1 axis blockade
1个月前
已完结
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
1个月前
已完结
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC
1个月前
已完结
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
1个月前
已完结
Promises and pitfalls of multi-cancer early detection using liquid biopsy tests
1个月前
已完结
Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer
1个月前
已完结
The next generation of immunotherapies for lung cancers
1个月前
已完结
Emerging importance of HER3 in tumorigenesis and cancer therapy
1个月前
已完结
皖公网安备34019202002308
